Skip to content
Contact Us
< Back to News

SanaClis Partners with Protara Therapeutics

1 minute read

September 6, 2022 -

SanaClis, a full service global CRO with an in-house clinical supply chain has recently partnered with Protara Therapeutics, a biotechnology company committed to identifying and advancing transformative therapies for people with cancer and rare diseases.

As part of Protara’s activities supporting their ongoing clinical trial operation in Europe, the company needed support with importation and QP Services from the United States to the European Union. QP services play a key role in bringing new products to market within the European Union and global clients, like Protara, seek highly experienced teams to ensure their clinical studies meet the required standards efficiently, cost effectively and on schedule.

By collaborating with SanaClis, Protara has been able to expedite timelines and maintain reliable and uninterrupted clinical supply and saw meaningful improvements in study activities after only 2 months of partnership. SanaClis was able to execute multiple QP audits and issued QP declaration, which helped enable Protara to conduct a clinical trial at sites in the European Union.

This collaboration is a great example of how SanaClis can effectively support global clients in conducting clinical programs with the highest standards, on time and on budget.

Related articles